Brown dog ticks, beware. Merial Ltd. has won permission from the U.S. Food and Drug Administration to add a label claim stating that the canine medication NexGard (afoxolaner) protects against a fourth tick species. The monthly preventive’s newest target is the brown dog tick (Rhipicephalus sanguineus), which is found throughout the lower 48 states and is linked to diseases such as Rocky Mountain spotted fever, anaplasmosis and ehrlichiosis. The Duluth, Ga., veterinary drug manufacturer in 2014 was allowed to promote NexGard’s effectiveness against black-legged (Ixodes scapularis) and lone star (Amblyomma americanum) ticks in addition to the initial claim for the American dog tick (Dermacentor variabilis). The prescription-only chewable tablet also is indicated to kill fleas. “When used as directed, NexGard has been shown to kill ticks all month long,” said Merial’s director of veterinary medical affairs, Doug Carithers, DVM. “Plus, it has the added benefit of killing fleas.” NexGard is not the only canine drug formulated to kill four common tick species. Merck Animal Health last year released a similar medication, Bravecto (fluralaner). Nexgard recently was named a 2015 Best New Product in the household category as part of a consumer survey conducted by Better Homes and Gardens magazine.
